A University of Manitoba research team is emerging as a global leader in COVID-19 anticoagulation trials thanks to their innovative, global trial studying different types of heparin, an anticoagulant (blood thinning) and anti-inflammatory drug. Early results released in January show full doses improved outcomes.
The ATTAC trial (antithrombotic therapy to ameliorate complications of COVID-19), is an international multi-platform randomized control trial (mpRCT) led by Ryan Zarychanski, a hematologist, critical care physician and associate professor. He has partnered with Patrick Lawler, at the Peter Munk Cardiac Centre and Ewan Goligher, from the University Health Network, both assistant professors at the University of Toronto….
